Pfizer piles on Tylenol with Advil ads, website

Share this article:
Pfizer piles on Tylenol with Advil ads, website
Pfizer piles on Tylenol with Advil ads, website
Pfizer took aim at Johnson & Johnson's Tylenol franchise with a campaign offering free Advil and urging consumers to clean out their medicine cabinets and trash recalled drugs.

The campaign includes TV, print and web ads, along with new websites and messaging savaging Tylenol both directly and indirectly. The company launched www.MedicineCabinetSafety.com, where visitors can get a free bottle of the OTC drug if they're among the first 500,000 eligible people to register for one. For that portion of the campaign, which urges regular pruning of medicine cabinets for expired or recalled products and gives tips for their safe disposal, the company has recruited Suzy Cohen, RPh and author of The 24-Hour Pharmacist, to offer advice.

Those recalled products, of course, would include McNeil Consumer's children's and infants' Tylenol and other OTC brands, subject to a cascading series of recalls due to manufacturing problems that started in April. As the Wall Street Journal noted, some of those products are going back on store shelves this week.

Visitors to www.takeactiontakeadvil.com can register to get free coupons there, as well, and can view a more blunt ad featuring upbeat music and the words: “Every day, thousands are switching from Tylenol to Advil. What are you waiting for?”

Pfizer, which took on Advil with its acquisition of Wyeth last year, is not the first competitor to kick Tylenol while it's down. In July, Novartis announced plans to distribute 250,000 bottles of Triaminic Fever Reducer Pain Reliever, which competes with children's Tylenol, free of charge as part of its launch of the line extension.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...